Weight Loss ETF Options: Tapping Into the GLP-1 Investment Wave

The weight-loss drug market is experiencing unprecedented growth, presenting a compelling investment opportunity for those seeking exposure to this transformative sector. With GLP-1 medications gaining mainstream adoption and oral formulations now proving competitive with injectable alternatives, weight loss ETF options have emerged as practical vehicles for capturing this market expansion. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound continue to lead the pharmaceutical landscape, while emerging competitors like Roche Holdings and smaller biotech firms are advancing promising pipeline candidates.

The confluence of clinical breakthroughs, favorable market dynamics, and expanding patient populations makes this an ideal moment to examine weight loss ETF investments. Recent data demonstrates that next-generation GLP-1 candidates are delivering improved efficacy alongside enhanced tolerability profiles—a significant shift from the current generation of weight-loss medications.

The GLP-1 Drug Revolution Takes Off

Clinical breakthroughs are reshaping the weight-loss pharmaceutical landscape at a remarkable pace. Recent studies from Roche, Novo Nordisk, and Terns Pharmaceuticals showcase the viability of oral GLP-1 formulations as legitimate alternatives to injectable treatments. Roche’s early Phase 1 clinical results revealed that its pill-based candidate achieved 6.1% weight loss in just four weeks across a small patient cohort of 12 individuals—typical for initial-stage research.

Novo Nordisk’s oral candidate demonstrated particularly impressive performance, outperforming the company’s flagship injectable product, Wegovy. Trial participants achieved 13.1% weight loss after 12 weeks on the pill formulation, compared to 6% after the equivalent period using Wegovy injections. Terns Pharmaceuticals’ early-stage candidate showed 4.9% weight loss over four weeks, aligning with competitive benchmarks, with the company planning to initiate Phase 2 testing in the coming year.

These oral formulations address critical patient concerns associated with current therapies. Traditional GLP-1 injectables frequently cause nausea, vomiting, and in more severe cases, intestinal blockage. Pill-based alternatives promise enhanced convenience through less frequent dosing and potentially fewer adverse effects—factors that could dramatically expand patient adoption.

Obesity as a Global Health Imperative

Understanding the market opportunity requires recognizing obesity’s enormous public health footprint. More than 1 billion individuals worldwide live with obesity, creating unprecedented demand for effective interventions. Obesity is strongly associated with serious health complications including diabetes, heart disease, stroke, and cancer.

GLP-1 medications work by mimicking glucagon-like peptide-1, a naturally occurring hormone produced in the intestine following food consumption. Originally developed for diabetes management, these drugs were subsequently discovered to regulate blood glucose levels, suppress appetite, and facilitate sustained weight loss. Contemporary research indicates that GLP-1 medications produce 10-20% reductions in body weight while simultaneously lowering cardiovascular death risk, heart attack incidence, and stroke probability by approximately 20%.

Market Expansion: The Numbers Tell a Compelling Story

Analysts from Morningstar and Pitchbook project that the weight-loss treatment sector will see 16 new drug approvals by 2029, with the overall market potentially expanding to $200 billion by 2031. These projections underscore the sector’s explosive growth trajectory.

Market research firm Spherical Insights offers even more ambitious forecasts, estimating the global weight-loss supplement market will expand from $28.65 billion in 2023 to $101.83 billion by 2033—representing a compound annual growth rate of 13.5%. This sustained double-digit growth reflects both the therapeutic advances in pharmacological treatments and intensifying consumer awareness around obesity management.

Three Weight Loss ETF Options for Investors

For investors seeking convenient exposure to this accelerating market, three weight loss ETF vehicles merit consideration:

Roundhill GLP-1 & Weight Loss ETF (OZEM)

The Roundhill GLP-1 & Weight Loss ETF holds the distinction of being the world’s first actively managed fund focused specifically on GLP-1 obesity treatments. Roundhill’s investment thesis emphasizes that weight-loss drugs represent one of the pharmaceutical industry’s most revolutionary advancements globally.

OZEM maintains 29 positions within its basket, with meaningful concentration in its top two holdings. Since inception in late May, the fund has accumulated $47.1 million in assets. The fund assesses annual expenses of 59 basis points and trades at an average daily volume of 34,000 shares, providing reasonable liquidity for most investors.

Amplify Weight Loss Drug & Treatment ETF (THNR)

Amplify’s weight loss ETF delivers diversified global exposure to companies engaged in GLP-1 pharmaceutical manufacturing and supporting businesses. The fund tracks the VettaFi Weight Loss Drug & Treatment Index and maintains 27 stocks in its portfolio, with substantial allocation to its two largest positions.

THNR charges 59 basis points annually and currently manages approximately $4.4 million in assets. Daily trading volume averages 3,000 shares, which may present considerations for investors requiring larger position sizes.

GLP-1, Obesity & Cardiometabolic ETF (HRTS)

This fund pursues long-term capital appreciation through investments in companies pioneering solutions for obesity and cardiometabolic diseases. The GLP-1, Obesity & Cardiometabolic ETF holds 45 stocks with a balanced allocation approach to top performers.

HRTS maintains $88.6 million in assets under management—the largest of the three vehicles discussed—and charges 75 basis points in annual fees. The fund executes approximately 25,000 shares daily on average, offering solid trading liquidity.

Selecting Your Weight Loss ETF Investment

Each weight loss ETF vehicle offers distinct characteristics suited to different investor preferences. OZEM provides focused, actively managed exposure with the smallest portfolio but concentrated bets on conviction holdings. THNR follows a systematic index methodology covering 27 companies with balanced fees. HRTS delivers the broadest diversification with 45 holdings and established scale, though at a marginally higher cost.

The convergence of clinical validation, market size projections, and regulatory momentum suggests this sector will command investor attention for years ahead. Whether through passive index-based weight loss ETF strategies or actively managed approaches, participating in this transformation has become more accessible than ever.